SensoDetect aims to capture 10% of a €6.8 Billion ASD and ADHD Diagnostics Market

"We're revolutionizing neurodiagnostics," declares PA Hedin, CEO of SensoDetect AB. "Our breakthrough SensoDetect Diagnostics (SDD) system will transform the current 6–18-month diagnostic process into a 30-minute clinical procedure, including world-first newborn screening capabilities. In a market serving 78 million undiagnosed cases, we're uniquely positioned to drive both clinical impact and strong returns."

Market Opportunity 

- €6.8B global ASD/ADHD diagnostics market 

- 1 in 36 children affected by ASD (CDC 2023) 

- Critical need for early intervention (before age 3) 

Proven Solution 

Objective ABR+AI analysis 

Mass screening capability 

Already deployed in Middle East clinics 

Revenue Drivers 

- Hardware: €2K-€50K/unit 

- Testing: €300/assessment (80% margins) 

- Telemedicine: €200/month subscriptions 

Growth Catalysts 

- 2025: Saudi commercialization 

- 2025: China NMPA approval

- 2026: China commercialization

- 2027: US expansion 

"What sets us apart," continues CEO Hedin, "is our ability to turn this healthcare crisis into a €6.8 Billion market opportunity while delivering life-changing screening and diagnostics. We're not just participating in the neurodiagnostic space - we're redefining it,” emphasizes CEO Hedin. "With secured regulatory approvals and clear regulatory pathways, we're targeting 10% market share by 2030." 

Data verified via [CDC](https://www.cdc.gov) | [SEC](https://www.sec.gov) | [SFDA](https://www.sfda.gov.sa)

SensoDetect AB is a Med Tech AI company listed on the Spotlight Stock Market. The company was founded in Lund in 2005, based on more than 30 years of research in clinical psychoacoustics at the Department of Neuroscience at Lund University. Initially, the focus was on patients with schizophrenia, as auditory hallucinations are a common symptom of the disease. However, today, the company offers a variety of other services within the product areas of diagnostics, medication, and health. The products are used in both private and public healthcare as a complement to other observations in ADHD, schizophrenia, and autism assessments, in measuring the effects of medication, and in hearing screening. SensoDetect's unique and globally patented technology reduces the economic impact on healthcare and society while providing patients and their families with faster and more reliable results.

More info at https://www.sensodetect.com/

For more information or partnership inquiries, please contact:

PA Hedin, CEO Sensodetect AB

+46 (0)46 15 79 04
pa.hedin@sensodetect.com

Läs mer på Cision